Use of a CB1 antagonist for treating negative symptoms of schizophrenia

Details for Australian Patent Application No. 2006321907 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Rogacki, Nancy; Black, Mark; Stevens, Rachel; Senyah, Yaw; Borowsky, Beth

Agent Watermark

Pub. Number AU-A-2006321907

PCT Pub. Number WO2007/067617

Priority 60/748,434 08.12.05 US

Filing date 7 December 2006

Wipo publication date 14 June 2007

International Classifications

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

3 July 2008 PCT application entered the National Phase

  PCT publication WO2007/067617 Priority application(s): WO2007/067617

4 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006321911-Biocompatible surgical compositions

2006321906-Uses of myostatin antagonists